25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BRAIN Biotech AG
Buy, Hold or Sell?

Let's analyze BRAIN Biotech AG together

I guess you are interested in BRAIN Biotech AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BRAIN Biotech AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BRAIN Biotech AG

I send you an email if I find something interesting about BRAIN Biotech AG.

1. Quick Overview

1.1. Quick analysis of BRAIN Biotech AG (30 sec.)










1.2. What can you expect buying and holding a share of BRAIN Biotech AG? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.64
Expected worth in 1 year
€-1.04
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€-1.67
Return On Investment
-70.5%

For what price can you sell your share?

Current Price per Share
€2.37
Expected price per share
€1.935 - €3.21
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of BRAIN Biotech AG (5 min.)




Live pricePrice per Share (EOD)
€2.37
Intrinsic Value Per Share
€-2.32 - €0.23
Total Value Per Share
€-1.69 - €0.86

2.2. Growth of BRAIN Biotech AG (5 min.)




Is BRAIN Biotech AG growing?

Current yearPrevious yearGrowGrow %
How rich?$15m$24.9m-$9.9m-65.7%

How much money is BRAIN Biotech AG making?

Current yearPrevious yearGrowGrow %
Making money-$12m-$8.9m-$3m-25.6%
Net Profit Margin-20.4%-15.0%--

How much money comes from the company's main activities?

2.3. Financial Health of BRAIN Biotech AG (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of BRAIN Biotech AG?

Welcome investor! BRAIN Biotech AG's management wants to use your money to grow the business. In return you get a share of BRAIN Biotech AG.

First you should know what it really means to hold a share of BRAIN Biotech AG. And how you can make/lose money.

Speculation

The Price per Share of BRAIN Biotech AG is €2.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BRAIN Biotech AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BRAIN Biotech AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.64. Based on the TTM, the Book Value Change Per Share is €-0.42 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BRAIN Biotech AG.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.55-23.3%-0.55-23.3%-0.41-17.4%-0.41-17.5%-0.45-19.0%
Usd Book Value Change Per Share-0.45-19.1%-0.45-19.1%-0.56-23.6%-0.07-2.8%0.114.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.45-19.1%-0.45-19.1%-0.56-23.6%-0.07-2.8%0.114.9%
Usd Price Per Share2.26-2.26-4.61-6.02-7.25-
Price to Earnings Ratio-4.08--4.08--11.22--17.59--18.21-
Price-to-Total Gains Ratio-4.98--4.98--8.27-1.95-3.80-
Price to Book Ratio3.27-3.27-4.03-4.13-5.62-
Price-to-Total Gains Ratio-4.98--4.98--8.27-1.95-3.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.572635
Number of shares388
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.45-0.07
Usd Total Gains Per Share-0.45-0.07
Gains per Quarter (388 shares)-175.97-26.20
Gains per Year (388 shares)-703.87-104.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-704-7140-105-115
20-1408-14180-210-220
30-2112-21220-314-325
40-2815-28260-419-430
50-3519-35300-524-535
60-4223-42340-629-640
70-4927-49380-733-745
80-5631-56420-838-850
90-6335-63460-943-955
100-7039-70500-1048-1060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.03.00.050.0%3.03.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.03.00.050.0%3.03.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BRAIN Biotech AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.418-0.4180%-0.514+23%-0.062-85%0.106-494%
Book Value Per Share--0.6360.6360%1.053-40%1.297-51%1.239-49%
Current Ratio--1.8261.8260%1.458+25%2.166-16%2.152-15%
Debt To Asset Ratio--0.8440.8440%0.676+25%0.636+33%0.654+29%
Debt To Equity Ratio--5.9335.9330%2.201+170%2.550+133%2.793+112%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value---29408210.400-29408210.4000%44928853.750-165%68623145.120-143%86208865.187-134%
Eps---0.509-0.5090%-0.379-26%-0.381-25%-0.414-19%
Ev To Ebitda Ratio--infinfnan%infnan%nannan%nannan%
Ev To Sales Ratio---0.538-0.5380%0.812-166%1.702-132%2.171-125%
Free Cash Flow Per Share---0.243-0.2430%-0.314+29%-0.305+25%-0.346+42%
Free Cash Flow To Equity Per Share---0.243-0.2430%-0.314+29%-0.305+25%-0.346+42%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.226--------
Intrinsic Value_10Y_min---2.324--------
Intrinsic Value_1Y_max---0.232--------
Intrinsic Value_1Y_min---0.290--------
Intrinsic Value_3Y_max---0.503--------
Intrinsic Value_3Y_min---0.826--------
Intrinsic Value_5Y_max---0.539--------
Intrinsic Value_5Y_min---1.310--------
Market Cap--45442789.60045442789.6000%92851853.750-51%118310145.120-62%135786698.520-67%
Net Profit Margin---0.204-0.2040%-0.150-27%-0.174-15%-0.190-7%
Operating Margin----0%-0%-0%-0%
Operating Ratio--1.6121.6120%1.563+3%1.610+0%1.608+0%
Pb Ratio3.729+12%3.2733.2730%4.035-19%4.134-21%5.621-42%
Pe Ratio-4.653-14%-4.084-4.0840%-11.215+175%-17.588+331%-18.207+346%
Price Per Share2.370+12%2.0802.0800%4.250-51%5.544-62%6.680-69%
Price To Free Cash Flow Ratio-9.747-14%-8.555-8.5550%-13.543+58%-19.024+122%-19.567+129%
Price To Total Gains Ratio-5.672-14%-4.978-4.9780%-8.265+66%1.949-355%3.800-231%
Quick Ratio--0.3210.3210%0.550-42%0.475-32%0.468-31%
Return On Assets---0.125-0.1250%-0.117-7%-0.105-16%-0.114-9%
Return On Equity---0.882-0.8820%-0.380-57%-0.416-53%-0.489-45%
Total Gains Per Share---0.418-0.4180%-0.514+23%-0.062-85%0.106-494%
Usd Book Value--15073253.00015073253.0000%24981697.000-40%30202517.800-50%28260811.583-47%
Usd Book Value Change Per Share---0.454-0.4540%-0.558+23%-0.068-85%0.115-494%
Usd Book Value Per Share--0.6900.6900%1.143-40%1.408-51%1.345-49%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value---31922612.389-31922612.3890%48770270.746-165%74490424.028-143%93579723.160-134%
Usd Eps---0.553-0.5530%-0.411-26%-0.414-25%-0.450-19%
Usd Free Cash Flow---5766176.000-5766176.0000%-7442188.000+29%-7062045.900+22%-7697280.500+33%
Usd Free Cash Flow Per Share---0.264-0.2640%-0.341+29%-0.331+25%-0.376+42%
Usd Free Cash Flow To Equity Per Share---0.264-0.2640%-0.341+29%-0.331+25%-0.376+42%
Usd Market Cap--49328148.11149328148.1110%100790687.246-51%128425662.528-62%147396461.243-67%
Usd Price Per Share2.573+12%2.2582.2580%4.613-51%6.018-62%7.251-69%
Usd Profit---12078358.500-12078358.5000%-8986854.500-26%-8825549.200-27%-9249907.333-23%
Usd Revenue--59301950.50059301950.5000%60066142.500-1%51254921.900+16%49688581.583+19%
Usd Total Gains Per Share---0.454-0.4540%-0.558+23%-0.068-85%0.115-494%
 EOD+3 -3MRQTTM+0 -0YOY+13 -225Y+8 -2710Y+8 -27

3.3 Fundamental Score

Let's check the fundamental score of BRAIN Biotech AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.653
Price to Book Ratio (EOD)Between0-13.729
Net Profit Margin (MRQ)Greater than0-0.204
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.321
Current Ratio (MRQ)Greater than11.826
Debt to Asset Ratio (MRQ)Less than10.844
Debt to Equity Ratio (MRQ)Less than15.933
Return on Equity (MRQ)Greater than0.15-0.882
Return on Assets (MRQ)Greater than0.05-0.125
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of BRAIN Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.329
Ma 20Greater thanMa 502.583
Ma 50Greater thanMa 1002.909
Ma 100Greater thanMa 2003.007
OpenGreater thanClose2.300
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About BRAIN Biotech AG

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit BRAIN Biotech AG earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • A Net Profit Margin of -20.4% means that €-0.20 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BRAIN Biotech AG:

  • The MRQ is -20.4%. The company is making a huge loss. -2
  • The TTM is -20.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-20.4%TTM-20.4%0.0%
TTM-20.4%YOY-15.0%-5.4%
TTM-20.4%5Y-17.4%-3.0%
5Y-17.4%10Y-19.0%+1.6%
4.3.1.2. Return on Assets

Shows how efficient BRAIN Biotech AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • -12.5% Return on Assets means that BRAIN Biotech AG generated €-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BRAIN Biotech AG:

  • The MRQ is -12.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.5%TTM-12.5%0.0%
TTM-12.5%YOY-11.7%-0.9%
TTM-12.5%5Y-10.5%-2.0%
5Y-10.5%10Y-11.4%+0.9%
4.3.1.3. Return on Equity

Shows how efficient BRAIN Biotech AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • -88.2% Return on Equity means BRAIN Biotech AG generated €-0.88 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BRAIN Biotech AG:

  • The MRQ is -88.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -88.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-88.2%TTM-88.2%0.0%
TTM-88.2%YOY-38.0%-50.2%
TTM-88.2%5Y-41.6%-46.6%
5Y-41.6%10Y-48.9%+7.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BRAIN Biotech AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient BRAIN Biotech AG is operating .

  • Measures how much profit BRAIN Biotech AG makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BRAIN Biotech AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient BRAIN Biotech AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.61 means that the operating costs are €1.61 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BRAIN Biotech AG:

  • The MRQ is 1.612. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.612. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.612TTM1.6120.000
TTM1.612YOY1.563+0.049
TTM1.6125Y1.610+0.003
5Y1.61010Y1.608+0.002
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BRAIN Biotech AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 1.83 means the company has €1.83 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BRAIN Biotech AG:

  • The MRQ is 1.826. The company is able to pay all its short-term debts. +1
  • The TTM is 1.826. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.826TTM1.8260.000
TTM1.826YOY1.458+0.368
TTM1.8265Y2.166-0.341
5Y2.16610Y2.152+0.014
4.4.3.2. Quick Ratio

Measures if BRAIN Biotech AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • A Quick Ratio of 0.32 means the company can pay off €0.32 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.321. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.321. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.321TTM0.3210.000
TTM0.321YOY0.550-0.229
TTM0.3215Y0.475-0.153
5Y0.47510Y0.468+0.007
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BRAIN Biotech AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of BRAIN Biotech AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BRAIN Biotech AG to industry mean.
  • A Debt to Asset Ratio of 0.84 means that BRAIN Biotech AG assets are financed with 84.4% credit (debt) and the remaining percentage (100% - 84.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BRAIN Biotech AG:

  • The MRQ is 0.844. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.844. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.844TTM0.8440.000
TTM0.844YOY0.676+0.168
TTM0.8445Y0.636+0.208
5Y0.63610Y0.654-0.018
4.5.4.2. Debt to Equity Ratio

Measures if BRAIN Biotech AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BRAIN Biotech AG to the  industry mean.
  • A Debt to Equity ratio of 593.3% means that company has €5.93 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BRAIN Biotech AG:

  • The MRQ is 5.933. The company is unable to pay all its debts with equity. -1
  • The TTM is 5.933. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ5.933TTM5.9330.000
TTM5.933YOY2.201+3.731
TTM5.9335Y2.550+3.383
5Y2.55010Y2.793-0.243
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings BRAIN Biotech AG generates.

  • Above 15 is considered overpriced but always compare BRAIN Biotech AG to the  industry mean.
  • A PE ratio of -4.08 means the investor is paying €-4.08 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BRAIN Biotech AG:

  • The EOD is -4.653. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.084. Based on the earnings, the company is expensive. -2
  • The TTM is -4.084. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.653MRQ-4.084-0.569
MRQ-4.084TTM-4.0840.000
TTM-4.084YOY-11.215+7.131
TTM-4.0845Y-17.588+13.504
5Y-17.58810Y-18.207+0.619
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BRAIN Biotech AG:

  • The EOD is -9.747. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.555. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.555. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.747MRQ-8.555-1.193
MRQ-8.555TTM-8.5550.000
TTM-8.555YOY-13.543+4.988
TTM-8.5555Y-19.024+10.470
5Y-19.02410Y-19.567+0.542
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of BRAIN Biotech AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 3.27 means the investor is paying €3.27 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BRAIN Biotech AG:

  • The EOD is 3.729. Based on the equity, the company is fair priced.
  • The MRQ is 3.273. Based on the equity, the company is fair priced.
  • The TTM is 3.273. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.729MRQ3.273+0.456
MRQ3.273TTM3.2730.000
TTM3.273YOY4.035-0.762
TTM3.2735Y4.134-0.861
5Y4.13410Y5.621-1.487
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets88,737
Total Liabilities74,851
Total Stockholder Equity12,617
 As reported
Total Liabilities 74,851
Total Stockholder Equity+ 12,617
Total Assets = 88,737

Assets

Total Assets88,737
Total Current Assets45,658
Long-term Assets43,078
Total Current Assets
Cash And Cash Equivalents 27,171
Short-term Investments 238
Net Receivables 7,798
Inventory 9,420
Other Current Assets 817
Total Current Assets  (as reported)45,658
Total Current Assets  (calculated)45,444
+/- 214
Long-term Assets
Property Plant Equipment 27,855
Long-term Assets Other 67
Long-term Assets  (as reported)43,078
Long-term Assets  (calculated)27,922
+/- 15,156

Liabilities & Shareholders' Equity

Total Current Liabilities25,006
Long-term Liabilities49,845
Total Stockholder Equity12,617
Total Current Liabilities
Accounts payable 5,611
Other Current Liabilities 5,757
Total Current Liabilities  (as reported)25,006
Total Current Liabilities  (calculated)11,368
+/- 13,638
Long-term Liabilities
Long term Debt 4,151
Long-term Liabilities Other 178
Long-term Liabilities  (as reported)49,845
Long-term Liabilities  (calculated)4,329
+/- 45,516
Total Stockholder Equity
Total Stockholder Equity (as reported)12,617
Total Stockholder Equity (calculated)0
+/- 12,617
Other
Capital Stock21,847
Common Stock Shares Outstanding 21,847
Net Invested Capital 16,768
Net Working Capital 20,652



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-09-302023-09-302022-09-302021-09-302020-09-302019-09-30
> Total Assets 
66,123
72,150
77,737
77,992
70,937
88,737
88,73770,93777,99277,73772,15066,123
   > Total Current Assets 
30,957
33,083
39,114
30,384
25,476
45,658
45,65825,47630,38439,11433,08330,957
       Cash And Cash Equivalents 
15,160
18,943
24,545
8,443
5,352
27,171
27,1715,3528,44324,54518,94315,160
       Short-term Investments 
63
103
105
362
178
238
23817836210510363
       Net Receivables 
6,388
6,165
6,722
8,036
9,442
7,798
7,7989,4428,0366,7226,1656,388
       Inventory 
7,926
6,964
7,011
9,624
9,756
9,420
9,4209,7569,6247,0116,9647,926
       Other Current Assets 
601
508
496
574
692
817
817692574496508601
   > Long-term Assets 
35,167
39,067
38,623
47,608
45,462
43,078
43,07845,46247,60838,62339,06735,167
       Property Plant Equipment 
0
24,469
24,291
28,736
28,720
27,855
27,85528,72028,73624,29124,4690
       Goodwill 
4,586
4,484
4,725
6,606
6,666
0
06,6666,6064,7254,4844,586
       Intangible Assets 
11,208
8,787
8,806
10,159
8,549
0
08,54910,1598,8068,78711,208
> Total Liabilities 
49,032
46,007
35,910
43,744
47,923
74,851
74,85147,92343,74435,91046,00749,032
   > Total Current Liabilities 
14,873
12,357
11,335
21,388
17,479
25,006
25,00617,47921,38811,33512,35714,873
       Short Long Term Debt 
0
0
1,567
1,734
3,218
0
03,2181,7341,56700
       Accounts payable 
4,428
3,171
3,831
6,754
5,617
5,611
5,6115,6176,7543,8313,1714,428
       Other Current Liabilities 
791
909
1,184
1,500
3,250
5,757
5,7573,2501,5001,184909791
   > Long-term Liabilities 
34,159
33,650
24,575
22,356
30,444
49,845
49,84530,44422,35624,57533,65034,159
       Capital Lease Obligations Min Short Term Debt
0
0
1,076
1,272
1,441
0
01,4411,2721,07600
       Long-term Liabilities Other 
64
3
736
1,710
965
178
1789651,710736364
> Total Stockholder Equity
12,234
20,785
38,783
29,638
21,771
12,617
12,61721,77129,63838,78320,78512,234
   Common Stock000000
   Retained Earnings Total Equity000000
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 000000
   Treasury Stock000000
   Other Stockholders Equity 000000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-09-30. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue54,631
Cost of Revenue-24,303
Gross Profit30,32830,328
 
Operating Income (+$)
Gross Profit30,328
Operating Expense-63,789
Operating Income-9,158-33,461
 
Operating Expense (+$)
Research Development0
Selling General Administrative4,974
Selling And Marketing Expenses0
Operating Expense63,7894,974
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,939
Other Finance Cost-44
Net Interest Income-1,983
 
Pretax Income (+$)
Operating Income-9,158
Net Interest Income-1,983
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,990-9,158
EBIT - interestExpense = -1,939
-11,127
-9,188
Interest Expense1,939
Earnings Before Interest and Taxes (EBIT)0-9,051
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-10,990
Tax Provision-111
Net Income From Continuing Ops-11,101-11,101
Net Income-11,127
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,983
 

Technical Analysis of BRAIN Biotech AG
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BRAIN Biotech AG. The general trend of BRAIN Biotech AG is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BRAIN Biotech AG's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BRAIN Biotech AG.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.61 < 2.94 < 3.21.

The bearish price targets are: 2.19 > 2.12 > 1.935.

Tweet this
BRAIN Biotech AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BRAIN Biotech AG. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BRAIN Biotech AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BRAIN Biotech AG. The current macd is -0.16692521.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BRAIN Biotech AG price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for BRAIN Biotech AG. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the BRAIN Biotech AG price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BRAIN Biotech AG Daily Moving Average Convergence/Divergence (MACD) ChartBRAIN Biotech AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BRAIN Biotech AG. The current adx is 42.79.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell BRAIN Biotech AG shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
BRAIN Biotech AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BRAIN Biotech AG. The current sar is 2.59743679.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BRAIN Biotech AG Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BRAIN Biotech AG. The current rsi is 36.33. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
BRAIN Biotech AG Daily Relative Strength Index (RSI) ChartBRAIN Biotech AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BRAIN Biotech AG. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BRAIN Biotech AG price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BRAIN Biotech AG Daily Stochastic Oscillator ChartBRAIN Biotech AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BRAIN Biotech AG. The current cci is -90.09506286.

BRAIN Biotech AG Daily Commodity Channel Index (CCI) ChartBRAIN Biotech AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BRAIN Biotech AG. The current cmo is -24.78592043.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BRAIN Biotech AG Daily Chande Momentum Oscillator (CMO) ChartBRAIN Biotech AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BRAIN Biotech AG. The current willr is -73.91304348.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that BRAIN Biotech AG is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BRAIN Biotech AG Daily Williams %R ChartBRAIN Biotech AG Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BRAIN Biotech AG.

BRAIN Biotech AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BRAIN Biotech AG. The current atr is 0.15648566.

BRAIN Biotech AG Daily Average True Range (ATR) ChartBRAIN Biotech AG Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BRAIN Biotech AG. The current obv is -159,344.

BRAIN Biotech AG Daily On-Balance Volume (OBV) ChartBRAIN Biotech AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BRAIN Biotech AG. The current mfi is 6.76794579.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BRAIN Biotech AG Daily Money Flow Index (MFI) ChartBRAIN Biotech AG Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BRAIN Biotech AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

BRAIN Biotech AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BRAIN Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.329
Ma 20Greater thanMa 502.583
Ma 50Greater thanMa 1002.909
Ma 100Greater thanMa 2003.007
OpenGreater thanClose2.300
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of BRAIN Biotech AG with someone you think should read this too:
  • Are you bullish or bearish on BRAIN Biotech AG? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BRAIN Biotech AG? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BRAIN Biotech AG

I send you an email if I find something interesting about BRAIN Biotech AG.


Comments

How you think about this?

Leave a comment

Stay informed about BRAIN Biotech AG.

Receive notifications about BRAIN Biotech AG in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.